- Home
- NUVL vs FIGR Comparison
NUVL vs FIGR Comparison
Compare NUVL & FIGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUVL | FIGR |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | 602 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.0B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NUVL | FIGR |
|---|---|---|
| Price | $104.60 | $37.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 9 |
| Target Price | ★ $134.75 | $53.22 |
| AVG Volume (30 Days) | 506.3K | ★ 3.4M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $69.23 |
| Revenue Next Year | $1,239.49 | $24.25 |
| P/E Ratio | ★ N/A | $134.36 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $70.25 | $25.01 |
| 52 Week High | $113.02 | $78.00 |
Technical Indicators
Market Signals| Indicator | NUVL | FIGR |
|---|---|---|
| Relative Strength Index (RSI) | 53.04 | 57.87 |
| Support Level | $97.91 | $37.23 |
| Resistance Level | $107.49 | $37.50 |
| Average True Range (ATR) | 3.83 | 2.06 |
| MACD | -0.18 | 0.39 |
| Stochastic Oscillator | 56.63 | 79.66 |
Price Performance
Historical ComparisonAbout NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About FIGR Figure Technology Solutions Inc.
Figure Technology Solutions Inc is building the future of capital markets with blockchain technology. proprietary technology powers next-generation lending, trading, and investing activities in areas such as consumer credit and digital assets. Its use of the blockchain ledger allows them to serve their end customers, improve speed and efficiency, and enhance standardization and liquidity. The Company operates as a single operating and reportable segment. The company's geographical operations is within the USA, with the majority of revenue from California.